Navigation Links
Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
Date:5/19/2011

n for the emergence of our PAD program."

"I am pleased to join the Board of Directors of Vermillion," said Bruce Huebner.  "Gail and her management team have made major strides in establishing Vermillion as a leading company in the area of cancer diagnostics.  OVA1 is an innovative product that provides valuable information to the physician for better patient care.  I look forward to helping the management team accelerate the growth of Vermillion."

In addition to serving as a director, Mr. Huebner is expected to lead a special committee of the Board to evaluate the current sales and marketing strategy for OVA1.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health.  Additional information about Vermillion can be found on the Web at www.vermillion.com.

About OVA1®

OVA1® is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers - Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta 2-Microglobulin (Beta 2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) - and a proprietary FDA-cleared software device to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned. Additional information about OVA1® can be found on the Web at www.ova-1.com.

Forward-Looking Statement

Certain
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
2. Vermillion Announces Receipt of NASDAQ Panel Decision
3. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
4. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
5. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
6. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
7. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
8. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
9. Vermillion Announces Issuance of European Patent
10. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
11. Stephens Initiates Coverage on Vermillion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
(Date:7/29/2015)... PARIS , July 30, 2015 ... de la santé, publie ses résultats pour le ... Brandicourt commente les résultats. Visionner ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire ... - Moteurs de croissance ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... as a "biotech hotspot," this time in e-mail newsletter ... state's profile and is just what the biotech industry ... list of five hotspots were California, Maryland, New Jersey ... the list, told Forbes it was a subjective ranking ...
... Innovation Center Back in the mid-1980s, encouraging economic ... public utilities. But then Plant Sites & Parks magazine ... U.S. , ,Jim Mohrbacher, who worked in corporate ... and mentioned to a colleague that he thought Madison ...
... Corporation is expanding into nearly 4,000 square feet of ... few minutes south of Madison. , ,Symphony CEO Ravi Kalla ... to be customized to make it possible to serve clients ... and video conferencing capabilities to allow contact with a hundred ...
Cached Biology Technology:Utilities help switch on economic development 2Utilities help switch on economic development 3Utilities help switch on economic development 4
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 /PRNewswire/ ... and services for gene function analysis and biomarker ... Guide RNA (sgRNA) Knockout Library targeting all human ... specifically and permanently "knock out" a gene,s function. ... provides a high throughput screening tool so that ...
(Date:7/21/2015)... 21, 2015 Today, ZTE announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... smartphone manufacturer in China and we are ... 5 for Axon , its ...
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... adult male sea turtles ( Caretta caretta ) using ... the potential risks posed to this threatened species by ... Toxicology and Chemistry , examines the different levels of ... turtles. "The risks posed by persistent organic pollutants ...
... BUFFALO, NY -- Exposure to air pollution early in life ... may alter her DNA and may be associated with premenopausal ... Buffalo have shown. The findings indicated that higher air ... increase levels of E-cadherin, a protein important to the adhesion ...
... in German . , Is the vacuum-packed ... not tell the whole story. And the "best-before" date is ... have added to the uncertainty, and the customer him- or ... This is an area in which a sensor film developed ...
Cached Biology News:Satellite tracking of sea turtles reveals potential threat posed by manmade chemicals 2Air pollution exposure affects chances of developing premenopausal breast cancer 2Rotten meat doesn't stand a chance 2
...
...
... I-96 Plate can be used either in ... large-scale (i.e., 96-well) purification of DNA and/or ... unique silica-based matrix make it perfect for ... RNA in = 10 l eluate per ...
Request Info...
Biology Products: